Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Al Jalila Children's Specialty Hospital Ink Rapid Whole-Genome Sequencing Deal

NEW YORK – Al Jalila Children's Specialty Hospital, based in Dubai, United Arab Emirates, said on Monday that it has signed a deal with Illumina to collaborate on rapid whole-genome sequencing for diagnosing critically ill children.

Under the terms of the agreement, the partners will collaborate on a two-year study of the impact of clinical rWGS in neonatal and pediatric care units. The study will comprise 200 children under the age of 18 and their parents. Illumina will provide sequencing reagents and analytical tools for rWGS.

Financial and other terms of the deal were not disclosed.

Al Jalila Children's genomic center has received CAP accreditation, the hospital said in a statement.

"We are committed to increasing genomic capability in the UAE," Illumina Chief Commercial Officer Susan Tousi said in a statement. "Our recently opened Dubai Solutions Center houses the latest sequencing technologies to provide even more support for our customers in the region, helping them deliver genomic precision medicine to an increasing number of patients."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.